ApoA-I inhibitors are compounds that belong to a chemical class designed to interact with and modulate the activity of apolipoprotein A-I (apoA-I). ApoA-I is a protein that plays a crucial role in lipid metabolism and transport, particularly in the formation of high-density lipoproteins (HDL) or good cholesterol. These inhibitors are developed to target the binding sites or interactions of apoA-I with lipids and other proteins involved in lipoprotein assembly and function.
By targeting apoA-I, these inhibitors provide a means to explore the intricate processes of HDL formation and cholesterol transport within the body. ApoA-I inhibitors enable researchers to investigate how modulating apoA-I's interactions with lipids influences the assembly, stability, and functionality of HDL particles. Additionally, studying the effects of apoA-I inhibitors may offer insights into their roles in cardiovascular health, lipid disorders, and other related conditions. Overall, apoA-I inhibitors serve as valuable tools for unraveling the complex interplay of proteins and lipids in maintaining lipid homeostasis and overall metabolic balance.
VEJA TAMBÉM
Nome do Produto | CAS # | Numero de Catalogo | Quantidade | Preco | Uso e aplicacao | NOTAS |
---|---|---|---|---|---|---|
Anacetrapib | 875446-37-0 | sc-364404 sc-364404A | 10 mg 50 mg | $615.00 $1785.00 | ||
Inibidor da CETP que modula os níveis de ApoA-I e o metabolismo lipídico relacionado. | ||||||
Dalcetrapib | 211513-37-0 | sc-364479 sc-364479A | 10 mg 50 mg | $720.00 $1900.00 | ||
Inibidor da CETP com impacto nos níveis de ApoA-I e no metabolismo lipídico. | ||||||
RVX 208 | 1044870-39-4 | sc-472700 | 10 mg | $340.00 | ||
Aumenta a transcrição de ApoA-I através da inibição do bromodomínio BET. |